Savant Capital LLC Acquires Shares of 62,914 Sana Biotechnology, Inc. $SANA

Savant Capital LLC purchased a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 62,914 shares of the company’s stock, valued at approximately $172,000.

Several other institutional investors and hedge funds have also bought and sold shares of SANA. Nisa Investment Advisors LLC raised its holdings in Sana Biotechnology by 673.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock worth $30,000 after purchasing an additional 9,501 shares in the last quarter. Hoey Investments Inc. purchased a new position in shares of Sana Biotechnology during the second quarter valued at about $33,000. Brooklyn Investment Group purchased a new position in shares of Sana Biotechnology during the first quarter valued at about $44,000. WealthPlan Investment Management LLC bought a new position in Sana Biotechnology in the second quarter worth about $48,000. Finally, CWM LLC raised its stake in Sana Biotechnology by 290.7% in the first quarter. CWM LLC now owns 38,431 shares of the company’s stock worth $65,000 after buying an additional 28,595 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Citizens Jmp lifted their price target on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th. JMP Securities set a $8.00 price objective on Sana Biotechnology in a research report on Thursday, October 30th. HC Wainwright dropped their target price on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Citigroup reaffirmed an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Finally, Wall Street Zen raised shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sana Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $3.23 on Friday. Sana Biotechnology, Inc. has a one year low of $1.26 and a one year high of $7.30. The business’s fifty day moving average is $4.20 and its 200 day moving average is $3.47. The stock has a market capitalization of $860.38 million, a PE ratio of -3.33 and a beta of 1.94.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. As a group, sell-side analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.